Spots Global Cancer Trial Database for Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor
Official Title: Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients
Study ID: NCT03023124
Conditions
Study Description
Brief Summary: Phase II randomized study for the comparison of trabectedin versus doxorubicin plus dacarbazine in patients with advanced solitary fibrous tumor
Detailed Description: Patients with solitary fibrous tumor will be randomized to receive 6 cycles of trabectedin or doxorubicin plus dacarbazine. In case of progression or unacceptable toxicity while under the experimental treatment prior to the completion of the 6 cycles, the patients will be offered to cross to the other arm (trabectedin arm to doxorubicin plus dacarbazine arm and vice versa).
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Nuovo Ospedale di Prato, Prato, Firenze, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, MI, Italy
Policlinico Universitario Campus Biomedico, Roma, RM, Italy
IRCCS Istituto ortopedico Rizzoli, Bologna, , Italy
Fondazione Del Piemonte Per L'Oncologia Ircc Di Candiolo -, Candiolo, , Italy
Ospedale Giaccone, Palermo, , Italy
Contact Details
Name: Silvia Stacchiotti, MD
Affiliation: Italian Sarcoma Group
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
